Challenges For Bioresorbable Stents In Peripheral Arterial Disease
Are bioresorbable stents for peripheral arterial disease losing their luster, even before getting to the market? Expectations for drug-eluting balloons seem to be soaring at stents’ expense.
You may also be interested in...
Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
Six-month data from the ESPRIT trial show that Abbott’s Esprit BVS, a peripheral stent based on the same technology as the Absorb BVS, reduces symptoms and keeps arteries open. Biotronik also announced that it has moved into the second phase of an MRI-compatibility trial of its Entovis pacemaker. More research news.
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.